Research: The Importance of Vitamin D for Multiple Sclerosis and Autoimmune Diseases

Introductory Note

This article is based on research originally published in the past and has been updated following scientific and informative criteria. The text is for informational purposes only and does not replace medical advice. For personal clinical decisions, always consult your doctor or specialists.

IN BRIEF

• Vitamin D is a biological factor that interacts with the immune system and bone metabolism; low levels are observationally associated with an increased risk of certain autoimmune diseases, including multiple sclerosis.
• Evidence includes observational studies, genetic analyses (Mendelian randomization), and clinical trials with heterogeneous results; causal evidence for many autoimmune diseases remains partial.
• For multiple sclerosis, epidemiological and genetic data suggest a protective role of higher 25(OH)D levels, but the therapeutic effect of supplementation is still uncertain.
• Practical interventions must consider baseline status, blood 25(OH)D levels, potential risks of overdose, and the balance with sun protection; each decision should be individually evaluated by a physician.

MAIN SECTION

Abstract: What does science say?

Vitamin D comprises compounds synthesized in the skin from UVB exposure and obtainable through food or supplements. The commonly measured form is 25-hydroxyvitamin D (25[OH]D). Observational studies show inverse associations between 25(OH)D levels and the risk of multiple sclerosis (MS) and some autoimmune diseases; genetic analyses based on population variants (Mendelian randomization) provide support for a plausible effect in some conditions, though not all. Clinical trials on supplementation report variable results: for some conditions, no clear reduction in events is observed, while in other contexts (deficient patients or specific subgroups), benefits may emerge. The overall reading suggests biological plausibility and consistent signals but not definitive proof of a universal causal effect: the dose-response relationship, timing (age of exposure), form of intervention (sun vs. supplement), and individual characteristics determine the outcomes.

Biological mechanisms and plausibility

Vitamin D modulates gene expression in various tissues, regulates immune cells (such as dendritic, T, and B cells), and influences calcium and bone mass metabolism. At the molecular level, 25(OH)D is converted into its active form (1,25[OH]2D), which binds to the vitamin D receptor (VDR) and can modulate pro- or anti-inflammatory responses, aiding immunological tolerance. These mechanisms provide a biological basis for the observed association between deficiency states and some autoimmune diseases, but the presence of a plausible mechanism does not equate to causal proof without consistent experimental support.

Types of available evidence

The evidence is structured into: population observational studies (associations between 25[OH]D levels, sun exposure, and disease risk), genetic studies (Mendelian randomization) that seek causal signals by exploiting variants related to vitamin D levels, and clinical supplementation trials. Each design has distinct limitations: observational data are sensitive to confounding and measurement bias; genetic analyses assume absence of pleiotropy and valid instruments; trials can be influenced by participant selection (e.g., not selected for deficiency) and the doses used. Robust inference requires critical integration of all these levels.

PRACTICAL SECTION

What it means in practice

For the general public: vitamin D is important for bone health and has documented immunomodulatory functions; low blood levels are correlated with an increased risk of some autoimmune diseases and worse outcomes in some observational series. However, supplementation to prevent autoimmune diseases is not universally proven: well-conducted trials have yielded conflicting results, partly because many studies did not selectively enroll people with actual vitamin D deficiency [1]. If there is suspicion of deficiency (symptoms, risk factors, or specific clinical conditions), a blood test (25[OH]D) and medical consultation are the correct way to decide on treatment and dosage. Unmonitored interventions or very high doses can carry risks (hypercalcemia, kidney stones), so management must be personalized.

Sun exposure, diet, and supplementation

Sun exposure is a natural source of vitamin D, and observational studies report that greater exposure in childhood and adolescence is associated with a lower risk of multiple sclerosis in adulthood [2][3]. However, sun exposure is a factor with skin risks: protection from photo-damage and melanoma prevention remain relevant. Diet alone rarely achieves adequate 25(OH)D levels without supplementation in deficiency conditions. When indicated, supplementation with cholecalciferol (vitamin D3) or calcifediol should be dosed and monitored by a physician to achieve appropriate target blood concentrations and reduce the risk of overdose [4].

Evidence on multiple sclerosis and autoimmune diseases

For multiple sclerosis, the evidence includes population studies, genetic analyses indicating potentially causal associations, and meta-analyses of clinical trials with non-uniform results [5][6]. Recent genetic analyses on large cohorts report genetic overlaps between 25(OH)D levels and MS risk, suggesting shared biological pathways but also complexity and possible non-linear effects [7]. In other autoimmune diseases, MR evidence shows heterogeneous results: some protective signals have emerged for specific conditions (e.g., psoriasis), while for other diseases, causal data are less solid [8].

KEY POINTS TO REMEMBER

• Vitamin D has known effects on bone metabolism and influences the immune system at a biological level; plausibility is supported by experimental and observational studies.
• Associations between low 25(OH)D levels and an increased risk of multiple sclerosis and some autoimmune diseases are consistent in many cohorts, but not all relationships demonstrate definitive causality.
• Genetic analyses (Mendelian randomization) strengthen the causal hypothesis in some cases, but the results are not homogeneous for all autoimmune diseases and show possible non-linearity.
• Supplementation trials have yielded variable results: benefits are more probable in subjects with documented deficiency; null or modest effects in unselected populations.
• A practical and prudent strategy is to measure 25(OH)D when there are risk factors or relevant conditions and discuss the need and dosage of supplementation with a doctor.

LIMITATIONS OF EVIDENCE

It is important to distinguish between association and causality. Observational studies show correlations but are susceptible to confounding (e.g., lifestyle, socioeconomic status, skin pigmentation). Mendelian randomization analyses reduce some biases but depend on the validity of genetic instruments and the absence of unwanted pleiotropic effects [8]. Clinical trials can be influenced by participant selection (often not selected for deficiency), the doses used, and follow-up; therefore, a negative trial in non-deficient populations does not refute a possible benefit in truly deficient individuals [4][9]. Furthermore, the timing of exposure (e.g., childhood exposure vs. adult exposure) can modify the impact on autoimmune susceptibility; this aspect requires longitudinal studies with early life data [3]. Finally, conflicting results between studies necessitate caution in interpretation and the adoption of clinical policies based on individual assessment.

Editorial Conclusion

Contemporary evidence positions vitamin D as a biomarker and potential risk modulator in some autoimmune diseases, with a more robust signal for multiple sclerosis than other disorders. However, biological complexity, methodological variability of studies, and non-homogeneous trial results require a cautious approach: targeted measurement of 25(OH)D status, correction of documented deficiency under medical supervision, and attention to the risks of over-supplementation. Future research should clarify the subgroups that benefit most, the role of exposure timing, and the effects of different dosages and formulations.

Editorial Note

This article collects and synthesizes scientific evidence available in the literature. The update was carried out with criteria of rigor and transparency: the primary sources used are listed in the "Scientific Research" section with DOI links to allow verification. The article is informative and does not constitute personalized medical recommendation; for clinical questions, consult a healthcare professional.

SCIENTIFIC RESEARCH

1. Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications. Autoimmun Rev. 2019. https://doi.org/10.1016/j.autrev.2019.102350.
2. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med. 2019; doi: https://doi.org/10.1056/NEJMoa1900906.
3. Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Mult Scler. 2014. doi: https://doi.org/10.1177/1352458513513968.
4. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med. 2015. doi: https://doi.org/10.1371/journal.pmed.1001866.
5. Association between 25(OH) vitamin D and multiple sclerosis: cohort, shared genetics, and causality. Nutr J. 2024. doi: https://doi.org/10.1186/s12937-024-01059-4.
6. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol. 2018. doi: https://doi.org/10.1007/s00415-018-9074-6.
7. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019; doi: https://doi.org/10.1001/jamanetworkopen.2019.17789.
8. Associations between vitamin D and autoimmune diseases: Mendelian randomization analysis. Semin Arthritis Rheum. 2023; doi: https://doi.org/10.1016/j.semarthrit.2023.152238.
9. Infections and Autoimmunity—The Immune System and Vitamin D: A Systematic Review. Nutrients. 2023; doi: https://doi.org/10.3390/nu15173842.
10. Past environmental sun exposure and risk of multiple sclerosis: role of VDR variant. (examples of case-control studies on sun exposure and MS). BMC Neurol. 2011; doi: https://doi.org/10.1186/1471-2377-11-123.

[If some bibliographic references or specific data are not present in the original article, the DOIs of the verified primary sources have been included. Any missing data are indicated in square brackets as a placeholder where necessary.]